Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Int J Mol Sci ; 22(1)2020 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-33396592

RESUMO

Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families. The drug also affects other kinases, including Src, Flt-3, LCK, LYN. Nintedanib is used in the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases and lung cancer. The mechanism of action suggests that nintedanib should be considered one of the potential agents for inhibiting and revising the fibrosis process related to COVID-19 infections. Due to the known induction of coagulation pathways during COVID-19 infections, possible interaction between nintedanib and anticoagulant seems to be an extremely important issue. In theory, nintedanib could increase the bleeding risk, thrombosis and lead to thrombocytopenia. The data from clinical trials on the concomitant use of nintedanib and antithrombotic agents is very limited as this patient group was within the standard exclusion criteria. Nintedanib is an important therapeutic option, despite its interaction with anticoagulants. If anticoagulant therapy is necessary, the more effective and safer option is the concomitant administration of DOACs and nintedanib, especially when drug-monitored therapy will be used in patients at high risk of bleeding complications.


Assuntos
Anticoagulantes/farmacologia , Hemorragia/etiologia , Indóis/farmacologia , Inibidores de Proteínas Quinases/farmacologia , Anticoagulantes/uso terapêutico , Antídotos/farmacologia , Antineoplásicos/farmacologia , Transtornos da Coagulação Sanguínea/complicações , Transtornos da Coagulação Sanguínea/tratamento farmacológico , COVID-19/complicações , COVID-19/metabolismo , Interações Medicamentosas , Hemorragia/epidemiologia , Humanos , Fibrose Pulmonar Idiopática/tratamento farmacológico , Indóis/efeitos adversos , Indóis/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Inibidores de Proteínas Quinases/efeitos adversos , Inibidores de Proteínas Quinases/uso terapêutico , Fatores de Risco , Tratamento Farmacológico da COVID-19
2.
Kardiol Pol ; 68(9): 1015-20, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20859892

RESUMO

BACKGROUND: Contrast-induced nephropathy (CIN) is a serious complication of percutenous coronary interventions (PCI). Proper hydration reduces the risk of PCI. Wheter oral hydration is as effective as intravenous one has not been well established. AIM: To determine the effects of oral hydration with mineral water versus intravenous hydration with isotonic solution (0.9% NaCl) on renal function in diabetic patients undergoing coronary angiography and angioplasty. METHODS: The study included 102 patients (age 67 ± 7.8 years, 44 female/58 male). Eligible patients (group 1 - 52 pts) were hydrated intravenously (1 mL/kg/h) 6 hours before and during 12 hours following PCI with isotonic solution (0.9% NaCl). Fifty patients (group 2) were randomised to receive oral mineral water (1 mL/kg/h) 6-12 hours before and during 12 hours following angiography or angioplasty. All patients during the procedure received contrast medium ioversol. Primary endpoint of the study was the evaluation of renal function before and 72 hours after contrast medium administration. RESULTS: Baseline creatinine clearance was 70.3 ± 21.22 mL/min in group 1 and 78.69 ± 19.92 mL/min in group 2 (NS). The mean volume of contrast medium was 101.1 ± 36.7 mL in group 1 and 110.4 ± 45.3 mL in group 2 (NS). At 72 hours after the procedure, creatinine clearance was 65.3 ± 23.39 mL/min in group 1 and 73.5 ± 21.94 mL/min in group 2 (NS). CONCLUSIONS: Our study demonstrates that the oral hydration with mineral water and intravenous hydration with 0.9% NaCl have similar effects on renal function in diabetic patients undergoing coronary angiography and angioplasty.


Assuntos
Injúria Renal Aguda/prevenção & controle , Angioplastia Coronária com Balão/efeitos adversos , Meios de Contraste/efeitos adversos , Angiografia Coronária/efeitos adversos , Angiopatias Diabéticas/terapia , Hidratação/métodos , Injúria Renal Aguda/induzido quimicamente , Administração Oral , Idoso , Angioplastia Coronária com Balão/métodos , Angiografia Coronária/métodos , Feminino , Taxa de Filtração Glomerular , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Águas Minerais/administração & dosagem , Medição de Risco , Fatores de Risco , Índice de Gravidade de Doença , Cloreto de Sódio/administração & dosagem , Equilíbrio Hidroeletrolítico
3.
Kardiol Pol ; 69(6): 593-4; discussion 595, 2011.
Artigo em Polonês | MEDLINE | ID: mdl-21678300

RESUMO

This report describes a case of a 40 year-old woman with implanted aortic prosthetic valve, who experienced thrombo-embolic complication in a form of ischaemic stroke in 15 week of pregnancy. At the beginning of the event, the patient suffered from mixed aphasia, right-side paresis and depressive syndrome. Thanks to cooperation of many specialists, especially rehabilitation team, she restored overall physical efficiency, speaking ability, delivered a healthy child, and returned to normal family and social activity. Problems of anti-thrombotic therapy during pregnancy in patients with prosthetic valves are discussed.


Assuntos
Valva Aórtica , Próteses Valvulares Cardíacas/efeitos adversos , Complicações Cardiovasculares na Gravidez , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/terapia , Adulto , Feminino , Humanos , Gravidez , Reabilitação do Acidente Vascular Cerebral
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA